Phibro Animal Health (NASDAQ:PAHC) Shares Gap Up After Strong Earnings

Phibro Animal Health Corporation (NASDAQ:PAHC)’s share price gapped up prior to trading on Thursday following a stronger than expected earnings report. The stock had previously closed at $32.20, but opened at $37.91. Phibro Animal Health shares last traded at $35.96, with a volume of 246,588 shares.

The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.52 by $0.05. Phibro Animal Health had a return on equity of 33.03% and a net margin of 3.73%.The firm had revenue of $378.70 million during the quarter, compared to analysts’ expectations of $362.24 million. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS.

Phibro Animal Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 24th. Stockholders of record on Wednesday, September 3rd will be issued a dividend of $0.12 per share. The ex-dividend date is Wednesday, September 3rd. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. Phibro Animal Health’s dividend payout ratio is 61.54%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on PAHC. Wall Street Zen upgraded shares of Phibro Animal Health from a “hold” rating to a “buy” rating in a research note on Friday, May 9th. BNP Paribas Exane raised shares of Phibro Animal Health from an “underperform” rating to a “neutral” rating and set a $24.00 price target for the company in a report on Monday, June 16th. JPMorgan Chase & Co. upgraded shares of Phibro Animal Health from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $25.00 to $35.00 in a research note on Monday, July 7th. BNP Paribas raised Phibro Animal Health to a “hold” rating in a research report on Monday, June 16th. Finally, Morgan Stanley set a $26.00 price target on Phibro Animal Health and gave the stock an “equal weight” rating in a research report on Wednesday, June 25th. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $24.40.

Institutional Investors Weigh In On Phibro Animal Health

Hedge funds have recently bought and sold shares of the stock. Nuveen LLC acquired a new position in shares of Phibro Animal Health in the 1st quarter valued at $10,312,000. Invesco Ltd. grew its position in Phibro Animal Health by 92.3% during the first quarter. Invesco Ltd. now owns 387,739 shares of the company’s stock valued at $8,282,000 after buying an additional 186,087 shares during the period. Ranger Investment Management L.P. increased its holdings in Phibro Animal Health by 101.1% in the second quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock valued at $9,143,000 after buying an additional 179,975 shares in the last quarter. Axecap Investments LLC acquired a new position in shares of Phibro Animal Health in the first quarter worth about $3,696,000. Finally, Millennium Management LLC raised its position in shares of Phibro Animal Health by 74.3% in the first quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after acquiring an additional 154,281 shares during the period. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Stock Performance

The company has a debt-to-equity ratio of 2.67, a quick ratio of 1.23 and a current ratio of 2.91. The firm has a market capitalization of $1.56 billion, a PE ratio of 32.59, a price-to-earnings-growth ratio of 0.54 and a beta of 0.80. The firm’s 50 day moving average price is $29.07 and its 200-day moving average price is $24.38.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.